title: Haloperidol decanoate (Janssen) in the treatment of schizophrenia.
abstract: Haloperidol decanoate inj. (Janssen) á 150 mg was evaluated during long-term (max. 4 years) treatment of 24 schizophrenics. The drug was very good tolerated locally and generally. Only lower doses of drug was sufficient to keep stabilized clinical state during the maintenance therapy (37.5-75 mg) with intervals 4-6 weeks. The occurrence of side effects gradually decreased similarly as a necessity to use antiparkinsonics. The maintenance treatment helped the patients to resume their social and working positions - 68% restarted working.
authors.affiliation: Department of Psychiatry, Medical School, Charles University, Hradec Králové.
authors.forename: J
authors.initials: J
authors.lastname: Zbytovský
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; C033563:haloperidol decanoate; D006220:Haloperidol